Drug Information

Drug (ID: DG01711) and It's Reported Resistant Information

• Name: Crenolanib/Trametinib
• Synonyms: Crenolanib/Trametinib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Hematologic cancer [ICD-11: 2B3Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Receptor-type tyrosine-protein kinase FLT3 (FLT3) [1]

• Molecule Alteration: Missense mutation; p.D835Y (c.2503G>T)
• Sensitive Disease: Hematologic Cancer [ICD-11: MG24.Y]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Ba/F3 cells; Colon; Homo sapiens (Human); CVCL_0161
• In Vitro Model: HEK 293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• Experiment for Molecule Alteration: Whole exome sequencing
• Experiment for Drug Resistance: MTS assay

References

• Ref 1: Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsNat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.